Health ❯ Healthcare ❯ Patient Care ❯ Treatment Efficacy

Survival Rates

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

An FDA expanded access pathway signals momentum ahead of a full Phase 3 reveal at ASCO on May 31.

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL